CTgyn common mistakes
CTgyn · Understand the traps and how to avoid them.
Assigning an ovarian primary to "ovary, NOS" (or defaulting to surface epithelial) whenever the pathology report describes a mucinous or endometrioid tumor without confirming the site of origin, even when the case involves a metastatic deposit to the ovary.
Candidates memorize that most ovarian cancers are surface epithelial and apply that prior to every case, ignoring the abstracting rule that metastatic tumors are coded to the primary site and that histology must be reconciled with the documented site of origin.
What to do instead
For every ovarian tumor, read the pathology and operative notes for phrases indicating metastasis (e.g., 'consistent with primary from...', 'metastatic adenocarcinoma'), then apply the primary-site rule and code histology from the confirmed primary. Practice with paired primary/metastatic case vignettes.
Recording FIGO stage from the narrative impression in the note rather than deriving it from the individual T, N, M and staging elements (tumor size, depth of invasion, nodal status, distant disease) documented in the record.
Staging tables are memorized as isolated facts, so candidates pattern-match a phrase like 'stage II' without verifying that the documented elements actually satisfy that stage, and they miss that clinical and pathologic stages may differ.
What to do instead
Build a habit of extracting each staging element into a worksheet first, then mapping to the FIGO/TNM stage and comparing with the documented stage; flag and query discrepancies instead of copying the narrative stage.
Treating cervical cancer clinical staging as if imaging and surgical findings could upgrade it, or assigning a lower stage when imaging shows lymph node involvement that the FIGO clinical staging rules do not incorporate.
Candidates transfer the general principle that more information means a more accurate stage from other sites, without learning that cervical cancer retains a clinical staging system with specific allowances (e.g., imaging and examination findings permitted, but nodal status handled per current rules).
What to do instead
Study the cervix-specific staging rules as a standalone checklist, including which modalities are allowed and which findings change stage; do timed drills on cervix vignettes that include imaging results and ask for the correct stage.
Coding laterality and site subsites of vulvar and vaginal primaries generically (e.g., 'vulva, NOS') when the record specifies labium majus, labium minus, clitoris, or overlapping subsites.
Candidates focus on histology and stage and treat topography as a low-effort field, not realizing subsite coding affects stage grouping, treatment comparisons, and data quality edits.
What to do instead
Use a topography cheat sheet for female genital sites during practice and always locate the exact subsite phrase in the operative or pathology report before coding; review edit failures for 'NOS' topography as a self-audit.
Confusing histologic grade systems across sites, applying a universal grade (e.g., FIGO grade 1-3) to tumors such as ovarian serous carcinoma or endometrial carcinoma where the grading scheme or its derivation from architectural vs nuclear features differs.
Candidates learn one grade scale and reuse it, missing that grade is site- and histology-specific and that some tumors (e.g., high-grade serous carcinoma) are defined by grade rather than graded on a scale.
What to do instead
Create a site-by-histology grade reference table and practice assigning grade only from the pathology report's stated system; when the report is ambiguous, mark for review rather than inferring.
Abstracting dates and treatment sequence incorrectly, such as recording the date of first course of treatment as the date of a diagnostic procedure or a neoadjuvant cycle, or failing to distinguish neoadjuvant from adjuvant therapy in the treatment fields.
Candidates skim the chronology and assume the first documented intervention is treatment, and they do not consistently apply the definition of first course of treatment, which excludes diagnostic/staging procedures.
What to do instead
For each case, build a dated timeline (diagnosis, staging surgery, systemic therapy, radiation) before coding treatment fields, and check each entry against the first-course definition; practice with cases containing neoadjuvant chemotherapy.
Omitting or misdating recurrence and subsequent treatment events, or counting a persistent/progressive disease as a recurrence, when reporting survival and follow-up data.
Candidates conflate recurrence with persistence and rely on the last note rather than the first documented evidence of recurrence, leading to wrong recurrence dates and biased survival intervals.
What to do instead
Define recurrence, persistence, and progression explicitly and apply the first-documented-evidence rule; practice computing disease-free and overall survival intervals from a set of follow-up notes with ambiguous language.
Ignoring the effect of lymph node dissection and omental/cytology findings on stage and prognostic factor fields, coding N0 or M0 when nodes were not sampled or cytology was not performed.
Candidates equate absence of documented positive findings with negative status, forgetting that pN0 requires pathologic examination and that pNX/pMX or clinical classification may apply when tissue was not sampled.
What to do instead
Before coding nodal and metastatic fields, confirm the record documents examination of nodes or cytology; otherwise code the appropriate not-assessed category and note the basis; drill with cases that have no lymphadenectomy.
Failing to recognize when a case requires a multiple-primary determination (e.g., synchronous endometrial and ovarian primaries versus metastasis) and coding it as a single primary without applying the relevant rules.
Candidates default to one primary per patient and do not apply the site-specific multiple-primary rules or the histologic and clinical criteria used to distinguish independent primaries from spread.
What to do instead
Review the multiple-primary rules for female genital sites and practice with synchronous tumor vignettes, documenting the reasoning for each primary determination; query the physician when criteria are not met in the record.
Breaching confidentiality or scope-of-practice standards by discussing identifiable case details in insecure channels or by making clinical judgments (e.g., altering a documented stage) instead of querying the responsible clinician.
Candidates treat registry work as purely technical and overlook the ethical and professional obligations around protected health information and the boundary between abstracting and clinical decision-making.
What to do instead
Memorize the confidentiality and query practices: use de-identified identifiers in communication, document queries formally, and never override clinician documentation without a resolved query; practice with ethics vignettes on data release and query escalation.